Renin-angiotensin system expression in the K562 human erythroleukaemic cell line

Local renin-angiotensin system (RAS) may affect leukaemic cell production within the bone marrow microenvironment.Angiotensin-converting enzyme (ACE), renin, and angiotensin could influence leukaemogenesis. In this study, mRNA expressions of the major RAS components (ACE, renin, and angiotensinogen)...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the renin-angiotensin-aldosterone system 2007-09, Vol.8 (3), p.145-147
Main Authors: Koca, Ebru, Haznedaroglu, Ibrahim C, Acar, Kadir, Beyazit, Yavuz, Aksu, Salih, Misirlioglu, Muge, Tuncer, Serdar, Sayinalp, Nilgun, Ozcebe, Osman I, Uner, Aysegul
Format: Article
Language:English
Subjects:
Angiotensinogen - genetics
Cell Line
Computer Systems
Humans
Leukemia, Erythroblastic, Acute - metabolism
Leukemia, Erythroblastic, Acute - pathology
Peptidyl-Dipeptidase A - genetics
Polymerase Chain Reaction
Renin - genetics
Renin-Angiotensin System
RNA, Messenger - analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Local renin-angiotensin system (RAS) may affect leukaemic cell production within the bone marrow microenvironment.Angiotensin-converting enzyme (ACE), renin, and angiotensin could influence leukaemogenesis. In this study, mRNA expressions of the major RAS components (ACE, renin, and angiotensinogen) in K562 human erythroleukaemia cell line have been searched by Real Time quantitative polymerase chain reaction. K562 blasts are multipotential, haematopoietic malignant cells that spontaneously differentiate into recognisable progenitors of the erythrocyte, granulocyte and monocytic series.We observed significant expressions of ACE, renin, and angiotensinogen in K562 leukaemic blast cells.Therefore, K562 human erythroleukaemia cell line may serve as an in vitro model to elucidate the role of RAS in leukaemia and to test the effects of RAS-affecting drugs on leukaemic cellular proliferation.
ISSN:1470-3203
1752-8976
DOI:10.3317/jraas.2007.019